Editas Medicine (EDIT) Accumulated Depreciation (2015 - 2023)

Editas Medicine (EDIT) has 9 years of Accumulated Depreciation data on file, last reported at $23.5 million in Q2 2023.

• Accumulated Depreciation for Q2 2023 came in at $23.5 million, up 26.38% year-over-year; the trailing twelve-month figure through Jun 2023 was $23.5 million (up 26.38% YoY), and the FY2022 annual result was $21.5 million, up 38.81% from the prior year.
• Accumulated Depreciation rose to $23.5 million in Q2 2023 per EDIT's latest filing, from $22.0 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $23.5 million in Q2 2023 and troughed at $5.1 million in Q1 2019.
• A 5-year average of $13.3 million and a median of $12.6 million in 2021 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2019 and 2020: Accumulated Depreciation increased 1.0% in 2019, then jumped 56.4% in 2020.
• A 5-year view of Accumulated Depreciation shows it stood at $7.2 million in 2019, then surged by 54.01% to $11.1 million in 2020, then surged by 39.77% to $15.5 million in 2021, then soared by 38.81% to $21.5 million in 2022, then advanced by 9.13% to $23.5 million in 2023.
• Business Quant data shows EDIT's Accumulated Depreciation at $23.5 million in Q2 2023, $22.0 million in Q1 2023, and $21.5 million in Q4 2022.